
Live Well Be Well with Sarah Ann Macklin | Health, Lifestyle, Nutrition This One Gut Microbe Could Decide If Cancer Treatment Works | William Li
Feb 6, 2026
William Li, physician-scientist known for gut microbiome and metabolism research, talks about Akkermansia muciniphila and its surprising roles. He covers how this keystone microbe links to insulin sensitivity, GLP-1 release, vascular and brain effects. He also explores associations between Akkermansia and cancer immunotherapy response, plus clinical implications for patient care.
AI Snips
Chapters
Transcript
Episode notes
Keystone Bacterium For Metabolism
- Akkermansia muciniphila is a recently discovered keystone gut bacterium that improves insulin sensitivity and glucose regulation.
- William Li highlights clinical studies showing it can lower hemoglobin A1c and sharpen metabolic control.
Microbe Links To GLP-1 And Circulation
- Akkermansia can stimulate the body's release of GLP-1, a hormone affecting metabolism and blood vessels.
- GLP-1 receptors exist on blood vessels throughout the body, including the brain, linking gut microbes to circulation and brain health.
Gut Microbe Predicts Immunotherapy Response
- Research found a strong association between Akkermansia presence and positive responses to cancer immunotherapy.
- Laurence Vogel's study showed responders had Akkermansia while non-responders lacked it, suggesting gut microbes affect immunotherapy success.

